Our objective was to predict the outcome of 90Y radioembolization in patients with
intrahepatic tumors from pretherapeutic baseline parameters and to identify predictive …

Purpose To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium
(Y)-90 radioembolization (RE). Methods We retrospectively analyzed the pre-therapeutic …

The aim of this work was to develop models for tumor control probability (TCP) in
radioembolization with 90Y PET/CT–derived radiobiologic dose metrics. Methods: Patients …

Purpose To evaluate whether lesion radiomics features and absorbed dose metrics
extracted from post-therapy 90 Y PET can be integrated to better predict outcomes in …

Aims The current prognostic model to estimate the survival in hepatocellular carcinoma
(HCC) patients treated with transarterial hepatic selective internal radiotherapy (SIRT) is not …

Purpose To evaluate the potential of imaging criteria in predicting overall survival of patients
with hepatocellular carcinoma (HCC) after a first transcatheter arterial yttrium-90 …

Purpose Previous external beam radiation therapy (EBRT) is theoretically contraindicated
for yttrium-90 (90 Y) radioembolization (RE) because the liver has a lifetime tolerance to …

Personalized dosimetry holds promise to improve radioembolization treatment outcomes in
hepatocellular carcinoma (HCC) patients. To this end, tolerance absorbed doses for …

We present a probabilistic approach to identify patients with primary and secondary hepatic
malignancies as responders or nonresponders to yttrium-90 radioembolization therapy …

166Ho-microspheres have recently been approved for clinical use for hepatic
radioembolization in the European Union. The aim of this study was to investigate the …